Article Text

Download PDFPDF
Activation of somatostatin receptors attenuates pulmonary fibrosis
  1. R Borie1,*,
  2. A Fabre1,2,*,
  3. F Prost1,
  4. J Marchal-Somme1,
  5. R Lebtahi3,
  6. S Marchand-Adam1,4,
  7. M Aubier1,4,
  8. P Soler1,
  9. B Crestani1,4
  1. 1
    INSERM, Unit 700, Paris, France, and Université Paris 7, Faculté de Médecine Denis Diderot, Paris, France
  2. 2
    Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Service d’Anatomopathologie, Paris, France
  3. 3
    Service de Médecine Nucléaire, Paris, France
  4. 4
    Service de Pneumologie A, Paris, France
  1. Professor B Crestani, Service de Pneumologie A, Hôpital Bichat-Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France; bruno.crestani{at}


Background and aim: Somatostatin analogues may have antifibrotic properties in the lung. The aim of this study was to evaluate the expression of the five somatostatin receptors sst1 to sst5 in normal and fibrotic mouse lung and the action of SOM230 (pasireotide), a new somatostatin analogue with a long half-life, in bleomycin induced lung fibrosis and in human lung fibroblasts in vitro.

Methods: After intratracheal injection of bleomycin, C57Bl6 male mice received one daily subcutaneous injection of SOM230 or saline. The lungs were evaluated on days 3, 7 and 14 after administration of bleomycin.

Results: We found that all somatostatin receptors were expressed in the normal mouse lung. The sst2 receptor mRNA expression was increased after bleomycin. SOM230 improved mice survival (69% vs 44%; p = 0.024), reduced lung collagen content at day 14 and decreased lung collagen-1 mRNA at day 7. SOM230 reduced bronchoalveolar lavage inflammatory cell influx at day 3, decreased lung connective tissue growth factor mRNA and transforming growth factor (TGF) β mRNA and increased lung hepatocyte growth factor and keratinocyte growth factor mRNA. The sst2 receptor was strongly expressed in the human lung (normal or fibrotic), particularly by fibroblasts. In vitro, SOM230 reduced BrdU incorporation by control human lung fibroblasts cultured under basal conditions or with TGFβ, and reduced alpha-1 collagen-1 mRNA expression in TGFβ stimulated fibroblasts.

Conclusion: We conclude that SOM230 attenuates bleomycin induced pulmonary fibrosis in mice and human lung fibroblasts activation. This study points to a potential new approach for treating pulmonary fibrotic disorders.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • * R Borie and A Fabre contributed equally to this work.

  • Funding: AF was supported by a grant from the Collège des Professeurs de Pneumologie and the Association Française pour la Recherche Thérapeutique. SM-A was supported by a grant from the Fondation pour la Recherche Médicale (Prix Mariane Josso). Part of this work was supported by the Legs Poix (Chancellerie des universités de Paris). PS is the recipient of a Contrat d'Interface Inserm-Assistance Publique/Hôpitaux de Paris.

  • Competing interests: None.

  • Ethics approval: Yes.

Linked Articles

  • Airwaves
    Wisia Wedzicha, Editor-in-Chief